Email david.wu@nus.edu.sg

Dr Wu is the Regional Director of Real World Evidence (RWE) & Health Economics (HE) in Market Access (Asia Pacific) at Johnson & Johnson Innovative Medicine. In this role, he is responsible for guiding cross-functional RWE strategy and tactics and HE to support market access, e.g. health technology assessment (HTA) submission and commercialization across product life cycle and all therapeutic areas.

Dr. Wu’s collaborative efforts extend globally, with partnerships formed with prestigious institutions such as the World Health Organization, the National Institutes of Health (USA), the United States Agency for International Development (USAID), and the Centers for Disease Control (CDC) in Taiwan. He has also lent his expertise to the Malaysian Ministry of Health and the Ministry of Health in the Philippines. Furthermore, he has provided advisory and technical support to numerous pharmaceutical companies in health economics and outcomes research.

Dr Wu has keen research interests in RWE, economic evaluation, evidence synthesis in HTA and statistical methodologies (e.g. Bayesian approach in censored cost-effectiveness data, surrogate endpoint validation and survival curve extrapolation) to address the issues faced by decision makers when dealing with complex health economics and outcomes research to inform health policy. He has co-authored more than 100 articles and/or abstracts published in renowned peer-reviewed journals including Value in Health, PharmacoEconomics, BMC Cancer, Vaccine, and Infectious Diseases & Therapy. He is also an editor and statistical adviser for a number of international journals.

Dr Wu is an enthusiastic educator who has taught various HEOR short courses at ISPOR Asia Pacific Conferences and delivered invited training courses to ISPOR regional chapters. He is currently a member of ISPOR, Taiwan and Singapore Chapters of ISPOR, and the Society for Medical Decision Making.

• NUS Saw Swee Hock School of Public Health (Adjunct)
• Regional Director of Real World Evidence & Health Economics, Janssen Pharmaceuticals (Primary)

• Real World Evidence
• Epidemiology
• Economic Evaluation / Economic Modeling
• Evidence Synthesis
• Statistical Methodologies In Health Economics And Outcomes Research
• Comparative Effectiveness Research
• Clinical Outcomes Assessment Methods

• SPH5405 (Introduction to Health Services Research)
• SPH5420 (Evidence synthesis for health technology assessment)
• MCI5009 (Health Services Research Methods for Clinicians)

• PhD in Biostatistics, National Yang Ming Chiao Tung University, Institute of Public Health, Taiwan
• M.Com in Statistics, Department of Statistics, College of Commerce, National Cheng Chi University, Taiwan
• BSc in Mathematics, Department of Mathematics, Soochow University, Taiwan

• Regional Director of Real World Evidence & Health Economics (Asia Pacific), Janssen Pharmaceuticals
• Lead Specialist (Economic Modeling), Agency for Care Effectiveness, Ministry of Health (Singapore)
• Senior Lecturer, Monash University Malaysia (Malaysia)
• Postgraduate Research Fellow, Chang Gung Memorial Hospital (Taiwan)

• Editor, Journal of Medical Economics
• Associate editor and statistical adviser, Archive of Pharmacy Practice
• Statistical editor, Journal of Clinical Practice and Health Sciences
• Reviewer editor, Frontiers in Pharmacology – Pharmaceutical Medicine and Outcomes Research
• ISPOR Asia Pacific Short Course Committee

• Wu DB, Tsai YW, Wen YW. (2012). Bayesian cost-effectiveness analysis for censored data – an application to antiplatelet therapy. Journal of Medical Economics 15(3):434-43.
• Wu DB, Chaiyakunapruk N, Beutels P. (2015). Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006-2014). Vaccine 33(14):1633-1658.
• Chong HY, Chaiyakunapruk N, Teoh SL, Wu DB, Kotirum S, Chiou CF. (2016). Global economic burden of schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment 12:357-73.
• Wu DB*, Lee KK, Roberts C, Lee VWY, Hong LW. (2016). Cost-effectiveness analysis of 13-and 10-valent pneumococcal conjugate vaccines for infants in Malaysia and Hong Kong. (*: Corresponding author) Human Vaccines & Immunotherapeutics 12(2):403-16.
• Wu DB, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson R, Smith PF, Kirkpatrick C, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Nelson R, Rayner CR. (2018). Cost-utility analysis of antiviral use under pandemic influenza using a novel approach – linking pharmacology, epidemiology and heath economics. Epidemiology and Infection 146(4):496-507. 15:1-12.
• Tan PT, Aziz Abdul MI, Pearce F, Wu DB*, Ng KH*. (2018). Erlotinib, gefitinib and afatinib for the first-line treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. (*: Co-corresponding author) BMC Cancer 18: 352
• Tan G, Aziz MI, Wu DB, Liang L, Tan PT, Ng K. (2018). Long-acting muscarinic antagonist monotherapy and combination therapy with long-acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: A network meta-analysis. International Journal of COPD 13:3203-3231
• Choon JWY, Wu DB*, Lo TL, Chung WS, Chui EMC, Tomlinson B, Lee VWY, Lee SC, Lee KKC. (2019). Real-world evidence of improved healthcare utilization in patients with recent onset schizophrenia after paliperidone palmitate once-monthly treatment in Hong Kong. (*: Corresponding author) Journal of Medical Economics, 22(3):273-279.
• Liu JY, Yu Z, Wu B, Wang S, Wu DB*, You RX. Cost-Effectiveness of testing for NS5A resistance to optimize treatment of elbasvir/grazoprevir for chronic hepatitis C in China. (2021) (*: Corresponding author). Frontiers in Pharmacology, section Drugs Outcomes Research and Policies Oct 15;12:717504. doi: 10.3389/fphar.2021.717504. eCollection 2021.
• Tsai IC, Yu DY, Wu DB*. Association between second progression-free survival and overall survival in metastatic castration-resistant prostate cancer in Japan: An analysis using national MDV claims database (*: Corresponding author). (2022) Curr Med Res Opin; 38(8):1351-1359. doi: 10.1080/03007995.2022.2096353.
• Wattanakamolkul K, Nakayama Y, Sbarigia U, Lim KH, Lacuesta VC, Tsai IC, Yu DY, Wu DB*. Epidemiology and treatment patterns of chronic hepatitis B virus in Japan: A nationwide population-based study using national MDV database. (2023) (*: Corresponding author). Infectious Diseases & Therapy https://doi.org/10.1007/s40121-023-00795-0
• Atsumi T, Tan JY, Chiang APC, Yu DY, Makanji Y, Wu DB*, Casorso J, Kouhkamari M, Lim S. Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus–pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan. (*: Corresponding author). (2023) Modern Rheumatology https://doi.org/10.1093/mr/road090
• Tan CK, Wu DB, Tan SYJ, Lin YY, Imran SS, Wee XT, Tan DSY. Validating the prognostic utility of the ABCD-GENE score in Asian patients with acute coronary syndrome patients on clopidogrel. (2023) European Cardiology Review European Cardiology Review DOI:https://doi.org/10.15420/ecr.2023.27
• Omura J, Makanji Y, Tanabe N, Yu DY, Tan JY, Lim S, Kouhkamari MH, Casorso J, Wu DB*, Bloomfield P. Comparative treatment persistence and adherence to endothelin receptor antagonists among patients with pulmonary arterial hypertension in Japan: A real-world administrative claims database study (*: Corresponding author). (2023) Pulmonary Therapy DOI: 10.1007/s41030-023-00244-w